1083 related articles for article (PubMed ID: 26599300)
21. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
[TBL] [Abstract][Full Text] [Related]
22. CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease.
Terrelonge M; Marder KS; Weintraub D; Alcalay RN
J Mol Neurosci; 2016 Jan; 58(1):88-92. PubMed ID: 26330275
[TBL] [Abstract][Full Text] [Related]
23. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
[TBL] [Abstract][Full Text] [Related]
24. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
[TBL] [Abstract][Full Text] [Related]
25. Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease.
Johar I; Mollenhauer B; Aarsland D
Int Rev Neurobiol; 2017; 132():275-294. PubMed ID: 28554411
[TBL] [Abstract][Full Text] [Related]
26. Association of Hippocampal Subfields, CSF Biomarkers, and Cognition in Patients With Parkinson Disease Without Dementia.
Becker S; Granert O; Timmers M; Pilotto A; Van Nueten L; Roeben B; Salvadore G; Galpern WR; Streffer J; Scheffler K; Maetzler W; Berg D; Liepelt-Scarfone I
Neurology; 2021 Feb; 96(6):e904-e915. PubMed ID: 33219138
[TBL] [Abstract][Full Text] [Related]
27. CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.
Kang JH; Mollenhauer B; Coffey CS; Toledo JB; Weintraub D; Galasko DR; Irwin DJ; Van Deerlin V; Chen-Plotkin AS; Caspell-Garcia C; Waligórska T; Taylor P; Shah N; Pan S; Zero P; Frasier M; Marek K; Kieburtz K; Jennings D; Tanner CM; Simuni T; Singleton A; Toga AW; Chowdhury S; Trojanowski JQ; Shaw LM;
Acta Neuropathol; 2016 Jun; 131(6):935-49. PubMed ID: 27021906
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
29. An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele.
Shahid M; Kim J; Leaver K; Hendershott T; Zhu D; Cholerton B; Henderson VW; Tian L; Poston KL
Neurobiol Dis; 2019 Jul; 127():278-286. PubMed ID: 30826425
[TBL] [Abstract][Full Text] [Related]
30. REM sleep behavior disorder and cerebrospinal fluid alpha-synuclein, amyloid beta, total tau and phosphorylated tau in Parkinson's disease: a cross-sectional and longitudinal study.
Nabizadeh F; Pirahesh K; Valizadeh P
J Neurol; 2022 Sep; 269(9):4836-4845. PubMed ID: 35426534
[TBL] [Abstract][Full Text] [Related]
31. Cortical Thinning Associated with Age and CSF Biomarkers in Early Parkinson's Disease Is Modified by the SNCA rs356181 Polymorphism.
Sampedro F; Marín-Lahoz J; Martínez-Horta S; Pagonabarraga J; Kulisevsky J
Neurodegener Dis; 2018; 18(5-6):233-238. PubMed ID: 30336481
[TBL] [Abstract][Full Text] [Related]
32. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
[TBL] [Abstract][Full Text] [Related]
33. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
34. α-Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies.
van Steenoven I; Majbour NK; Vaikath NN; Berendse HW; van der Flier WM; van de Berg WDJ; Teunissen CE; Lemstra AW; El-Agnaf OMA
Mov Disord; 2018 Nov; 33(11):1724-1733. PubMed ID: 30440090
[TBL] [Abstract][Full Text] [Related]
35. [Subtypes of mild cognitive impairment in Parkinson's disease and factors predicting its becoming dementia].
Toribio-Diaz ME; Carod-Artal FJ
Rev Neurol; 2015 Jul; 61(1):14-24. PubMed ID: 26108904
[TBL] [Abstract][Full Text] [Related]
36. Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson's disease.
Murakami H; Tokuda T; El-Agnaf OMA; Ohmichi T; Miki A; Ohashi H; Owan Y; Saito Y; Yano S; Tsukie T; Ikeuchi T; Ono K
BMC Neurol; 2019 Jun; 19(1):113. PubMed ID: 31164098
[TBL] [Abstract][Full Text] [Related]
37. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia.
Mollenhauer B; Trenkwalder C; von Ahsen N; Bibl M; Steinacker P; Brechlin P; Schindehuette J; Poser S; Wiltfang J; Otto M
Dement Geriatr Cogn Disord; 2006; 22(3):200-8. PubMed ID: 16899997
[TBL] [Abstract][Full Text] [Related]
38. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
Reijs BLR; Ramakers IHGB; Köhler S; Teunissen CE; Koel-Simmelink M; Nathan PJ; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Vandenberghe R; Johannsen P; Blackwell A; Vanderstichele H; Verhey F; Visser PJ
J Alzheimers Dis; 2017; 60(3):1119-1128. PubMed ID: 28984585
[TBL] [Abstract][Full Text] [Related]
39. Cerebrospinal fluid α-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer's disease.
Mackin RS; Insel P; Zhang J; Mohlenhoff B; Galasko D; Weiner M; Mattsson N
J Alzheimers Dis; 2015; 43(3):1007-16. PubMed ID: 25125463
[TBL] [Abstract][Full Text] [Related]
40. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease.
Pagano G; De Micco R; Yousaf T; Wilson H; Chandra A; Politis M
Neurology; 2018 Sep; 91(10):e894-e905. PubMed ID: 30089615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]